2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13B.11 Clinical Outcomes of Continuous Immunotherapy Beyond Progression in Patients with Extensive-Stage Small Cell Lung Cancer

EP.13B.11 Clinical Outcomes of Continuous Immunotherapy Beyond Progression in Patients with Extensive-Stage Small Cell Lung Cancer

Back to course

Pdf Summary

The study conducted by Chengjun Wang and colleagues at Qilu Hospital of Shandong University and other institutions evaluated the efficacy of continuous immunotherapy beyond progression in patients with extensive-stage small cell lung cancer (ES-SCLC) after initial immunochemotherapy. The study included 183 ES-SCLC patients treated with first-line immunochemotherapy, with a majority receiving anti-PD-L1 or anti-PD-1 antibodies. The patients’ median age was 64 years, with most being male and having a history of smoking.<br /><br />Following progression after first-line treatment, patients were offered various second-line therapies, including continuous immunotherapy, chemotherapy with and without immunotherapy, and combinations involving anti-angiogenic therapy. The results demonstrated that continuous immunotherapy provided a numerically longer median progression-free survival (PFS) of 3.43 months compared to 2.40 months in the chemotherapy-only group.<br /><br />The inclusion of anti-angiogenic agents alongside immunotherapy showed the most extended PFS, indicating potential survival benefits for patients undergoing such combined therapies. Although the overall survival data is not yet mature, the findings suggest that continuous use of immune checkpoint inhibitors (ICIs) beyond progression, especially with anti-angiogenic strategies, may offer benefits.<br /><br />The study highlights the potential value of continuous ICIs and anti-angiogenic agents in extending survival in ES-SCLC after initial treatment fails. However, further research is needed to fully understand the long-term efficacy and safety of these treatment approaches. Overall, the study opens the possibility of improving clinical outcomes for patients with ES-SCLC through strategic second-line treatment regimens.

Asset Subtitle

Jisheng Li

Meta Tag

Speaker Jisheng Li

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

continuous immunotherapy

extensive-stage small cell lung cancer

ES-SCLC

anti-PD-L1

anti-PD-1

immunochemotherapy

progression-free survival

anti-angiogenic therapy

immune checkpoint inhibitors

second-line treatment